Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Phase 1 Active not recruiting

210 enrolled

DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Skin Neoplasms

NCT04004442 2026-03-13

COAXIN

Phase 1 Active not recruiting

19 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03719768 2026-03-02

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Phase 1 Completed

16 enrolled

CNS

Brain Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT03252938 2026-02-19

INSIGHT

Phase 1 Active not recruiting

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT05396833 2026-02-19

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Phase 1 Active not recruiting

120 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05081180 2026-01-23

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase 1 Active not recruiting

17 enrolled

CNS

Neoplasms, Central Nervous System Neoplasms

Clinical Trials

PAveMenT

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

COAXIN

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

INSIGHT

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors